Background: Adequate MRI-based staging of early rectal cancers is essential for decision-making in an era of organ-conserving treatment approaches. The aim of this population-based study was to determine the accuracy of routine daily MRI staging of early rectal cancer, whether or not combined with endorectal ultrasonography (ERUS).

Methods: Patients with cT1–2 rectal cancer who underwent local excision or total mesorectal excision (TME) without downsizing (chemo)radiotherapy between 1 January 2011 and 31 December 2018 were selected from the Dutch ColoRectal Audit. The accuracy of imaging was expressed as sensitivity, specificity, and positive predictive value (PPV) and negative predictive value.

Results: Of 7382 registered patients with cT1–2 rectal cancer, 5539 were included (5288 MRI alone, 251 MRI and ERUS; 1059 cT1 and 4480 cT2). Among patients with pT1 tumours, 54.7 per cent (792 of 1448) were overstaged by MRI alone, and 31.0 per cent (36 of 116) by MRI and ERUS. Understaging of pT2 disease occurred in 8.2 per cent (197 of 2388) and 27.9 per cent (31 of 111) respectively. MRI alone overstaged pN0 in 17.3 per cent (570 of 3303) and the PPV for assignment of cN0 category was 76.3 per cent (2733 of 3583). Of 834 patients with pT1N0 disease, potentially suitable for local excision, tumours in 253 patients (30.3 per cent) were staged correctly as cT1N0, whereas 484 (58.0 per cent) and 97 (11.6 per cent) were overstaged as cT2N0 and cT1–2N1 respectively.

Conclusion: This Dutch population-based analysis of patients who underwent local excision or TME surgery for cT1–2 rectal cancer based on preoperative MRI staging revealed substantial overstaging, indicating the weaknesses of MRI and missed opportunities for organ preservation strategies.

*Members of the Dutch ColoRectal Audit Group are co-authors of this article and can be found under the heading Collaborators

Introduction

Rectal cancer management depends on clinical locoregional staging by endoscopy, endorectal ultrasonography (ERUS) and MRI. The decision whether to treat rectal cancer either by rectum-sparing local excision or radical excision, with or without the addition of preoperative (chemo)radiotherapy ((C)RT), is dictated by clinical staging and identification of risk factors such as T category, suspicious lymph nodes and extramural venous invasion. The use of MRI for determining indication for preoperative radiotherapy and extent of subsequent rectal resection in patients with intermediate- or high-risk rectal cancer has significantly influenced rectal cancer care worldwide.
The introduction of bowel cancer screening programmes has resulted in stage migration, with an increase in early-stage rectal cancer (cT1–2 N0)\(^3\). This opens opportunities for organ preservation, avoiding substantial morbidity and decreased function associated with radical rectal resection\(^2\). However, correct patient selection with optimal staging is a prerequisite for a safe organ preservation strategy\(^4\). Superficial lesions (T1) without risk features and/or suspicious lymph nodes might be considered suitable for upfront local excision as part of an organ-preserving strategy. However, the final pathology may reveal more advanced tumour stage or the presence of adverse features leading to completion total mesorectal excision (TME) or adjuvant CRT within current trials\(^5\,\,\,6\).

Another approach aimed at organ preservation for patients with early cancer is upfront (C)RT with subsequent response assessment and tailored adjuvant treatment (such as TME surgery, local excision, watch-and-wait strategy) within current trials. Although this approach is promising, a substantial proportion (about 50 per cent) of patients are at risk of overtreatment, especially given the current limitations of clinical staging\(^7\,\,\,8\).

To avoid both undertreatment and overtreatment, optimizing clinical staging is of utmost importance. MRI-based staging of rectal cancer has proven value in more advanced stages of the disease, but is known for its limited accuracy in early rectal cancers and assessment of lymph node status\(^9\). The diagnostic value largely depends on MRI protocols and experience of the radiologist. For early lesions, the addition of ERUS has been advocated to improve clinical staging, but this seems highly operator-dependent\(^10\). At present, population-based data on the accuracy of clinical tumour and nodal staging of early rectal cancer are lacking. Therefore, the aim of this population-based study was to determine the diagnostic accuracy of routine MRI staging, with or without ERUS, in patients who underwent local excision or TME surgery for cT1–2 rectal cancer.

### Methods

Data were derived from the Dutch ColoRectal Audit (DCRA). This audit collects detailed information on patient, tumour and treatment characteristics, and short-term outcomes (within 90 days) from all patients undergoing resection for primary colorectal cancer in the Netherlands. Specific details of the DCRA regarding data collection, data quality, data validation and methodology have been published previously\(^11\).

### Patient selection

All patients who underwent local excision or TME surgery for primary cT1–2 rectal cancer, and were registered in the DCRA between 1 January 2011 and 31 December 2018, were potentially eligible. Only patients who were staged by MRI, with or without ERUS, were included. Exclusion criteria were: downsizing therapy (such as short-course radiotherapy (SCRT) with delayed surgery or CRT), a registered (yp)T0 tumour, emergency surgery, and staging by modalities other than MRI with or without ERUS. Patients who underwent SCRT with immediate surgery (interval to surgery 2 weeks or less) were considered eligible. For this study, no ethical approval or informed consent was required under Dutch law.

### Data extraction and outcome parameters

The following data were extracted from the DCRA database: patient and tumour characteristics, and diagnostic, staging and procedural data. Data on ERUS were available in the DCRA data set until 2017. Removal of this variable was related to the low uptake of ERUS at a national level and registration burden. Pathological T and N categories were extracted as the standard for comparison with radiological staging. Undertaging of patients with rectal cancer was defined by a higher pTN compared with cTN category, and overstaging by a lower pTN compared with cTN category.

Outcome parameters included sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of preoperative MRI in determining tumour and node categories.

### Dutch colorectal cancer guidelines

The Dutch colorectal cancer guideline of 2008\(^12\) was revised in 2014\(^13\). To determine the cT category of rectal cancer, both Dutch guidelines recommended MRI as part of the standard evaluation of non-superficial tumours. ERUS can be considered in addition to MRI for differentiating T1 from T2 disease. Regarding nodal staging, the Dutch guideline of 2008\(^12\) stated that lymph nodes larger than 5 mm on MRI should be considered suspicious for nodal metastasis. The revised 2014 guideline\(^13\) stated that nodal disease should be considered in lymph nodes with a size of 5–9 mm and the presence of at least two of three malignant morphological characteristics, or in lymph nodes measuring more than 9 mm.

### Statistical analysis

Baseline characteristics are described as numbers with percentages. Staging was evaluated for patients who underwent MRI alone, and those who had combined imaging by MRI and ERUS. To calculate the diagnostic
Table 1 Patient, tumour and treatment characteristics of patients with cT1–2 rectal cancer diagnosed by MRI with or without endorectal ultrasonography between 2011 and 2018, who subsequently underwent local excision or total mesorectal excision without downsizing preoperative radiotherapy

| Characteristic                              | TME surgery (n = 4847) | Local excision (n = 692) |
|---------------------------------------------|------------------------|--------------------------|
| **Age (years)**                             |                        |                          |
| < 75                                        | 3508 (72·4)            | 497 (71·9)               |
| ≥ 75                                        | 1336 (27·6)            | 194 (28·1)               |
| Missing                                     | 3                      | 1                        |
| **Sex**                                     |                        |                          |
| M                                           | 2997 (61·9)            | 461 (66·6)               |
| F                                           | 1848 (38·1)            | 231 (33·4)               |
| Missing                                     | 2                      | 0                        |
| **ASA fitness grade**                       |                        |                          |
| I–II                                        | 4000 (82·5)            | 532 (76·9)               |
| ≥ III                                       | 846 (17·5)             | 160 (23·1)               |
| Missing                                     | 1                      | 0                        |
| **Charlson score**                          |                        |                          |
| 0                                           | 2619 (54·0)            | 349 (50·4)               |
| 1                                           | 1044 (21·5)            | 166 (24·0)               |
| ≥ 2                                         | 1184 (24·4)            | 177 (25·6)               |
| Missing                                     | 1                      | 0                        |
| **BMI (kg/m²)**                             |                        |                          |
| < 30                                        | 3889 (81·6)            | 578 (84·0)               |
| ≥ 30                                        | 879 (18·4)             | 110 (16·0)               |
| Missing                                     | 79                     | 4                        |
| **Preoperative MRI staging**                |                        |                          |
| MRI alone                                   | 4700 (97·0)            | 588 (85·0)               |
| MRI including ERUS                          | 147 (3·0)              | 104 (15·0)               |
| **Tumour distance from anus (cm)*           |                        |                          |
| ≤ 5                                         | 1564 (33·7)            | 354 (56·0)               |
| 6–10                                        | 1820 (39·3)            | 224 (35·4)               |
| ≥ 10                                        | 1252 (27·0)            | 54 (8·5)                 |
| Missing                                     | 211                    | 60                       |
| **Clinical tumour category**                |                        |                          |
| cT1                                         | 577 (11·9)             | 482 (69·7)               |
| cT2                                         | 4270 (88·1)            | 210 (30·3)               |
| cN0                                         | 3746 (77·4)            | –                        |
| cN1                                         | 942 (19·5)             | –                        |
| cN2                                         | 81 (1·7)               | –                        |
| cNx/unknown                                 | 69 (1·4)               | –                        |
| Missing                                     | 9                      | 9                        |
| **Clinical node category**                  |                        |                          |
| cN0                                         | 4542 (93·9)            | –                        |
| cN1                                         | 82 (1·7)               | –                        |
| cNx/unknown                                 | 215 (4·4)              | –                        |
| Missing                                     | 8                      | 8                        |
| **Clinical metastasis category**            |                        |                          |
| cM0                                         | 3227 (66·6)            | 689 (99·6)               |
| cM1                                         | 1620 (33·4)            | 3 (0·4)                  |
| cMx/unknown                                 | 3 (0·4)                | –                        |
| **Neoadjuvant radiotherapy**                |                        |                          |
| None                                        | 3115 (64·3)            | –                        |
| SCRT-1S                                     | 1044 (21·5)            | –                        |
| **Surgical procedure**                      |                        |                          |
| (L)AR                                       | 1057 (21·8)            | 507 (73·3)               |
| APR                                         | 3231 (48·1)            | 168 (24·3)               |
| Hartmann                                    | 1403 (28·9)            | 17 (2·5)                 |
| Other†                                      | 56 (1·2)               | 0 (0)                    |
| **Pathological tumour category**            |                        |                          |
| pT1                                         | 1046 (21·6)            | –                        |
| pT2                                         | 294 (6·1)              | –                        |
| pNx/unknown                                 | 42 (0·9)               | –                        |
| **Pathological node category**              |                        |                          |
| pN0                                         | 3465 (71·5)            | –                        |
| pN1                                         | 1046 (21·6)            | –                        |
| pNx/unknown                                 | 294 (6·1)              | –                        |
| **Circumferential resection margin**        |                        |                          |
| Positive (≤ 1 mm)                           | 119 (2·7)              | –                        |
| Negative                                    | 4222 (97·3)            | –                        |
| Missing                                     | 506                    | –                        |
Accuracy of staging MRI for early rectal cancer

Table 1 Continued

| No. of lymph nodes retrieved | TME surgery (n = 4847) | Local excision (n = 692) |
|-----------------------------|------------------------|--------------------------|
| ≤ 10                        | 1060 (21.9)            | –                        |
| > 10                        | 3779 (78.0)            | –                        |
| Unknown                     | 8 (0.2)                | –                        |
| No. of positive lymph nodes |                        |                          |
| 0                           | 3492 (72.1)            | –                        |
| 1–3                         | 1034 (21.4)            | –                        |
| > 3                         | 317 (6.9)              | –                        |
| Missing                     | 4                      | –                        |

Values in parentheses are percentages, excluding missing values. *Not defined in Dutch ColoRectal Audit until 2016 and mostly based on endoscopic measurement of distance to anal verge; since 2016 defined as distance to anorectal junction on sagittal MRI. †Includes proctocolectomy and total colectomy. TME, total mesorectal excision; ERUS, endorectal ultrasonography; SCRT-IS, short-course radiotherapy–immediate surgery (within 2 weeks); (L)AR, low anterior resection; APR, abdominoperineal resection.

Table 2 Clinical versus pathological tumour category assignment by MRI alone, including local excisions

| pT1 | pT2 | pT3 | pT4 | Total |
|-----|-----|-----|-----|-------|
| cT1 | 656 | 197 | 85  | 942   |
| cT2 | 792 | 2191| 1311| 4346  |
| Total| 1448| 2388| 1396| 5288  |

Table 3 Clinical versus pathological nodal staging by MRI alone

| pN0 | pN1 | pN2 | pNx | Total |
|-----|-----|-----|-----|-------|
| cN0 | 2733| 672 | 178 | 3615  |
| cN1 | 524 | 311 | 89  | 930   |
| cN2 | 46  | 15  | 18  | 79    |
| cNx | 36  | 24  | 3   | 67    |
| Total| 3339| 1022| 288 | 4691* |

* cN/pN was missing for nine patients.

Table 4 Clinical versus pathological tumour category assignment by MRI and endorectal ultrasonography, including local excisions

| pT1 | pT2 | pT3 | Total |
|-----|-----|-----|-------|
| cT1 | 80  | 31  | 6    | 117   |
| cT2 | 36  | 80  | 18   | 134   |
| Total| 116 | 111 | 24   | 251   |

Table 5 Clinical versus pathological nodal staging by MRI and endorectal ultrasonography

| pN0 | pN1 | pN2 | Total |
|-----|-----|-----|-------|
| cN0 | 106 | 22  | 3    | 131   |
| cN1 | 10  | 1   | 1    | 12    |
| cN2 | 1   | 0   | 1    | 2     |
| cNx | 2   | 0   | 0    | 2     |
| Total| 119 | 23  | 5    | 147   |

Table 6 Diagnostic accuracy of clinical staging of combined T and N category by MRI alone

| pT1 N0 | pT2 N0 | pT1–2 N1 | Total |
|--------|--------|----------|-------|
| cT1 N0 | 253    | 87       | 47    | 387   |
| cT2 N0 | 484    | 1312     | 289   | 2085  |
| cT1–2 N1| 97     | 279      | 177   | 553   |
| Total  | 834    | 1678     | 513   | 3025* |

* Tumours were staged as ‘other’ in 1675 patients (35.6 per cent).

Results

A total of 7382 patients with cT1–2 rectal cancer were identified between 2011 and 2018. Patient selection is shown in Fig. S1 (supporting information). During the study interval, the use of MRI for clinical staging in this performance of imaging, cT and cN categories were compared with pT and pN categories. Both local excisions and TME were included in the analysis of T category, whereas only TME was included in the analysis of N category. Sensitivity, specificity, PPV and NPV were calculated, with 95 per cent confidence intervals, for analyses of cT1, cT2, cN0, cN1 and cN2. These outcome parameters were also calculated by year, and analysed for time trends using the linear-by-linear association test for the total study interval (2011–2018), and comparing two time periods (before 2014 versus 2014 onwards) to explore the impact of revision of the national colorectal cancer guideline in 2014. Regarding N category, nodal positivity (N+) was used without discriminating N1 from N2. P < 0.050 was considered statistically significant. Statistical analyses were performed in SPSS® for Windows® version 24.0 (IBM, Armonk, New York, USA).
population increased from 90-4 per cent in 2011 to 92-6 per cent in 2018. A total of 5539 patients remained for final analysis after exclusion of those who had preoperative (C)RT with an interval of more than 2 weeks to surgery, those treated in an emergency setting, and patients whose tumours were staged by means other than MRI with or without ERUS. Staging was performed by MRI alone in 5288 patients, and combined imaging by MRI and ERUS in 251. The use of ERUS in combination with MRI increased from 0-2 per cent in 2011 to 5-4 per cent in 2017. Some 1059 patients (19-1 per cent) had cT1 and 4480 (80-9 per cent) had cT2 disease.

Patient, tumour and treatment characteristics of the included patients are shown in Table 1, stratified by type of surgery. The median number of lymph nodes examined increased from 11 in 2011 to 15 in 2018 (Fig. S2, supporting information). The proportion of pN+ disease remained similar over time (median 28 per cent), as well as the total number of positive lymph nodes in patients with pN+ disease (median 2).

### Diagnostic performance for tumour category

The diagnostic performance of preoperative MRI alone and with the addition of ERUS was assessed by tumour and node category (Tables 2–6). Of 942 patients with cT1 disease, 656 (69-6 per cent) had pT1, 197 (20-9 per cent) had pT2 and 85 (9-0 per cent) had pT3 tumours. Of 4346 patients with cT2 disease, 792 (18-2 per cent) had pT1, 2191 (50-4 per cent) had pT2 and 1311 (30-2 per cent) had pT3 tumours (Table 2). Overstaging of pT1 tumours occurred in 54-7 per cent and understaging of pT2 tumours in 8-2 per cent. The sensitivity and specificity of MRI alone were 45-3 and 92-6 per cent respectively for T1 tumours, and 91-8 and 25-7 per cent for T2 tumours (Table 7). Overall, assignment of cT1–2 category of rectal cancer by MRI alone was accurate in 2847 patients (53-8 per cent); 792 patients (15-0 per cent) were overstaged clinically in terms of category, and 1649 (31-2 per cent) were understaged clinically. Combining the results for cT1–2 tumours evaluated by MRI alone, 26-4 per cent were pT3 and 1-1 per cent were pT4 lesions.

In patients who were staged by both MRI and ERUS, overstaging of pT1 occurred in 31-0 per cent (36 of 116) and understaging of pT2 in 27-9 per cent (31 of 111) (Table 4). The sensitivity and specificity of combined MRI and ERUS was 69-0 and 72-6 per cent respectively for T1 tumours, with corresponding values of 72-1 and 61-4 per cent for T2 tumours (Table 8).

Trends in sensitivity, specificity, PPV and NPV by individual clinical tumour category over the study interval

### Table 7 Accuracy of MRI alone for tumour and node staging

| Tumour category, including local excisions | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Accuracy (%) |
|------------------------------------------|----------------|----------------|---------|---------|--------------|
| cT1                                      | 45-3 (42-7, 47-9) | 92-6 (91-7, 93-4) | 69-6 (66-9, 72-2) | 81-8 (81-1, 82-5) | 79-6 (78-5, 80-7) |
| cT2                                      | 91-8 (90-6, 92-8) | 25-7 (24-1, 27-3) | 50-4 (49-8, 51-0) | 79-1 (76-5, 81-4) | 55-5 (54-2, 56-9) |

### Table 8 Accuracy of MRI and endorectal ultrasonography for tumour and node staging

| Tumour category, including local excisions | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Accuracy (%) |
|------------------------------------------|----------------|----------------|---------|---------|--------------|
| cT1                                      | 69-0 (59-7, 77-2) | 72-6 (64-3, 79-9) | 68-4 (61-6, 74-5) | 73-1 (67-1, 78-5) | 70-9 (64-9, 76-5) |
| cT2                                      | 72-1 (62-8, 80-2) | 61-4 (52-8, 69-5) | 59-7 (53-8, 65-3) | 73-5 (66-7, 79-4) | 66-1 (59-9, 72-0) |

Values in parentheses are 95 per cent confidence intervals. PPV, positive predictive value; NPV, negative predictive value.
are shown in Fig. 1. The PPV of MRI for staging cT1 tumours showed a significant increase of 32.1 per cent between 2011 and 2018 ($P < 0.050$). NPV decreased significantly from 89.6 to 80.7 per cent in same interval ($P < 0.050$) (Fig. 1a). For cT2 tumours, the specificity showed a significant increase of 9.4 per cent from 2013 to 2018 ($P < 0.050$) and there was a significant increase in PPV of 4.5 per cent from 2012 to 2018 ($P < 0.050$) (Fig. 1b).

Assessment of tumour category for local excisions

In patients who were staged by MRI alone and underwent local excision, overstaging of pT1 occurred in 23.5 per
Fig. 2 Clinical node categories and diagnostic indices for clinical mesorectal lymph node assignment based on MRI (cN0 and cN1–2 versus pN0 and pN1–2) in patients with cT1–2 rectal cancer based on MRI for each year, 2011–2018

Clinical node category is shown for all patients who underwent surgical resection of rectal cancer. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) are shown with 95 per cent intervals. *P < 0.050 over total study interval (linear-by-linear association test).

cent (100 of 426) and understaging of pT2 in 45.2 per cent (66 of 146) (Table S1, supporting information). For the local excision group, the sensitivity and specificity of MRI alone were 76.5 and 56.2 per cent respectively for T1 tumours, and 54.8 and 74.9 per cent for T2 tumours (Table S2, supporting information).

For patients who underwent local excision and were staged by MRI and ERUS, overstaging of pT1 occurred in 12 per cent (10 of 81) and understaging of pT2 in 59 per cent (13 of 22) (Table S3, supporting information). The sensitivity and specificity of MRI and ERUS combined were 87.7 and 39.1 per cent respectively for T1 tumours, and 40.9 and 87.8 per cent for T2 tumours (Table S4, supporting information).

Diagnostic performance for node category

Preoperative assessment of node category was available for 4769 patients who had TME (98.4 per cent). The proportion of patients with missing cN category in the population decreased from 3.5 per cent in 2011 to 0.7 per cent in 2018. Assessment of overall node category was accurate in 3066 patients (65.4 per cent) by MRI alone; nodal disease was understaged clinically in 977 patients (20.8 per cent) and overstaged clinically in 570 (12.2 per cent) (Table 3). Using MRI alone, the accuracy for cN0 category was 69.0 per cent, with a sensitivity of 82.7 per cent and specificity of 33.8 per cent (Table 7). Overstaging of pN0 disease occurred in 17.3 per cent (570 of 3303), and understaging of pN1–2 in 66.3 per cent (850 of 1283).

Tumours in 131 patients were assigned as cN0 by combined MRI and ERUS, of which 25 were pN1–2 (19.1 per cent) (Table 5). The accuracy for cN0 category by MRI and ERUS was 75.2 per cent, with a sensitivity of 90.6 per cent and specificity of 10.7 per cent (Table 8).

In this population of patients with cT1–2 rectal cancer assessed by MRI who underwent TME, there was a
A decreasing trend in diagnosis of cN1–2 disease after revision of the guideline in 2014 (Fig. 2). The sensitivity for determination of node category by MRI showed a significant increase from 74.0 per cent in 2012 to 87.6 per cent in 2018 (P < 0.050). A significant decrease in PPV was observed from 80.8 per cent in 2014 to 75.3 per cent in 2018 (P < 0.050). Additional time-trend analysis showed a significant decrease in specificity over the total study period (P = 0.031) and between the two time intervals (before 2014 versus 2014 onwards) (P = 0.039).

### Diagnostic accuracy of combined tumour and node staging by MRI

The clinically relevant combined staging according to T and N category was evaluated (Table 6). Among 834 patients with pT1 N0 disease, potentially suitable for local excision only, tumours were correctly staged as cT1 N0 in 253 (30.3 per cent), but overstaged as cT2 N0 in 484 patients (58.0 per cent) and cT1–2 N1 in 97 patients (11.6 per cent). Eighty-seven of 1678 pT2 N0 tumours (5.2 per cent) and 47 of 513 pT1–2 N1 tumours (9.2 per cent) were staged incorrectly as cT1 N0. Of 513 patients with pT1–2 N1 disease, 177 (34.5 per cent) were correctly staged by MRI alone.

### Discussion

In the present study, the diagnostic value of MRI for tumour and nodal staging was determined specifically for early tumour stages. Most studies reporting on the diagnostic performance of MRI included all stages of rectal cancer. The meta-analyses of Al-Sukhni and colleagues, including 21 studies, and Bipat et al., including 90 studies, demonstrated overall sensitivities ranging from 69 to 87 per cent, and specificities of 75–82 per cent for determination of T category by MRI. Patients with rectal cancer who underwent preoperative downsizing therapy were excluded from the meta-analysis reported by Zhang and co-workers comprising a total of 35 studies. Subgroup analyses for T1 and T2 tumours showed sensitivities of 58 and 80 per cent respectively (45–3 and 91–8 per cent in the present study) and specificities of 97 and 74 per cent (92–6 and 25–7 per cent here). In accordance with the present findings, a high specificity for cT1 and a high sensitivity for cT2 disease were reported.

The diagnostic value of nodal staging by MRI remains a subject of debate. The revised Dutch colorectal cancer guideline from 2014 specifically included stricter criteria for lymph node positivity on MRI. Remarkably, a significant decrease in specificity for nodal staging was observed from 2014 (P = 0.039), meaning that an increased tendency toward overstaging was observed over time in this population of early rectal cancers, despite current guideline recommendations. In a study of 52 patients with T1–3 rectal cancer, preoperative nodal staging by MRI had an accuracy of 60 per cent, sensitivity of 57 per cent and specificity of 83 per cent. In another study that evaluated 65 early rectal cancers, the accuracy was 84 per cent, with a PPV of 71 per cent and NPV of 90 per cent for MRI-based nodal staging. The present study confirmed the overstaging by MRI for nodal disease in this specific group of patients with early tumours, in which 56–3 per cent of cN1 tumours were pN0. A possible explanation for overstaging might be based on the use of size criteria for nodal staging and hospital variation in adherence to guidelines. Overstaging of positive nodal disease with use of over 5 mm as a size criterion, which was a recommendation in the colorectal cancer guideline of 2008, has been reported in 30–40 per cent. In the TESAR trial, which is investigating therapeutic options after local excision of early rectal cancer with risk features, lymph nodes smaller than 10 mm are considered benign independent of morphological features.

Radiologists have a learning curve to become proficient in staging of early rectal cancer by MRI. Rafaelsen and colleagues reported a higher sensitivity (96 versus 77 per cent; P < 0.050) and specificity (74 versus 40 per cent; P < 0.050) for more experienced gastrointestinal radiologists compared with general radiologists in assessing all
stages of rectal cancer. This implies that specific training programmes and accreditation for radiologists is likely to improve the accuracy of early rectal cancer staging\textsuperscript{21}. Furthermore, tumour staging improves with the use of higher field strength MRI and review of images ideally by consensus of two or more expert radiologists\textsuperscript{16,17}. Recently, the national SPECC (significant polyps and early colorectal cancer) initiative in the UK expressed the need to improve staging of early rectal cancer, including better focus on standardization of MRI protocols, consensus guidelines, (size) criteria used for nodal staging, structured MRI reporting, and increasing performance and experience in smaller centres\textsuperscript{3,21}.

The European Society of Gastrointestinal and Abdominal Radiology consensus document explicitly mentions the role of (additional) ERUS, given its superior diagnostic performance in differentiating T1 from T2 tumours\textsuperscript{22}. In the present study, the addition of ERUS only slightly improved nodal staging in comparison with MRI alone, and showed overstaging of pT1 and understaging of pT2, but numbers were small because of the restricted use of ERUS in the Netherlands. As these modalities are complementary to each other, the reported accuracy should be interpreted as such, and not as the sole accuracy of MRI or ERUS. A recent study\textsuperscript{23} showed that ERUS outperformed MRI in overall T, T1, T3 and overall nodal staging ($P<0.010$). These results support the suggestion that ERUS is better at detecting smaller lesions in the thinner colorectal wall (submucosa and serosa) in contrast to the muscularis propria (T2), at which level MRI performs better. However, Mondal and co-workers\textsuperscript{24} showed no benefit of ERUS in patient selection for local therapy, with less than 10 per cent change in management when results of ERUS were considered alongside clinical, endoscopic and MRI staging findings.

Given the diagnostic difficulties in MRI staging as found in the present analysis, upfront CRT strategies carry a risk of overtreatment as many small T1 lesions will be included that could be treated with local excision only. The potential of upfront (C)RT in organ preservation is currently being investigated in an international controlled trial\textsuperscript{6,25}. Another more pragmatic strategy aimed at organ preservation for cT1–2 tumours of limited size is diagnostic/therapeutic local excision. Exact histopathology will reveal the final staging and, for the majority, radical local excision with endoscopic submucosal dissection (ESD) or transanal minimally invasive surgery (TAMIS) already constitutes definitive treatment for low-risk T1 tumours. If the final pathology shows an intermediate-risk early cancer (high-risk pT1 or low-risk pT2), additional treatment options should be considered: completion TME surgery, adjuvant CRT, or close surveillance including MRI for local and/or nodal regrowth. However, the last two of these options are still considered experimental. Implementing diagnostic/therapeutic local excision by ESD or TAMIS for all cT1–2 tumours requires patient as well as surgeon and multidisciplinary team education. Patients should be aware of the possibility that completion TME is advised if the final pathology reveals high-risk features. However, completion TME is regarded as a slightly riskier procedure because it is associated with higher morbidity and colostomy rates, and risk of incomplete specimens, compared with primary TME\textsuperscript{26}. However, these increased risks seem less evident with transanal TME\textsuperscript{27}. In addition, the potential problems of subsequent completion surgery should be considered before deciding on local excision, and full-thickness excisions should be avoided in areas at risk of breach of completion TME surgery (anterior rectum and close to sphincter). Alternative therapeutic approaches, adjuvant CRT and close surveillance with endoscopy and MRI are experimental arms in the ongoing TESAR trial\textsuperscript{6,25}.

The strength of this population-based study is that it provides real-life data concerning the diagnostic accuracy of preoperative MRI staging of early rectal cancer in daily practice in the Netherlands. However, some limitations need to be addressed. Patients who underwent endoscopic polypectomy of a T1 cancer, or were referred to dedicated units in pursuit of a rectum-preserving strategy were not included, which might have influenced the overall diagnostic accuracy of MRI and ERUS. The decision-making process regarding the use of additional ERUS for staging was not registered in the DCRA data set. Furthermore, no data were available regarding the different MRI protocols used to stage rectal cancer across the centres. Furthermore, the variables currently available in the DCRA do not allow analyses of the percentage of patients who could eventually have been spared TME surgery based on all currently known high-risk features available to guide this decision, or who needed completion TME if routine upfront local excision had been implemented.

This large population-based study demonstrated the diagnostic value of preoperative MRI in patients who underwent local excision or TME surgery for early rectal cancer in routine daily practice in the Netherlands between 2011 and 2018. It revealed a substantial rate of overstaging of pT1 N0 tumours, which eliminated the option of an organ-preserving approach instead of TME surgery in eligible patients.

**Collaborators**

Members of the Dutch ColoRectal Audit Group: A. G. J. Aalbers (Department of Surgery, Netherlands Cancer
Accuracy of staging MRI for early rectal cancer

Institute—Antoni van Leeuwenhoek, Amsterdam); W. A. Bemelman (Department of Surgery, Amsterdam UMC, location AMC, Amsterdam); F. C. den Boer (Department of Surgery, Zaans Medisch Centrum, Zaandam); S. O. Breukink (Department of Surgery, MUMC, Maastricht); P. P. L. O. Coene (Department of Surgery, Maassstad Ziekenhuis, Rotterdam); P. G. Doornebosch (Department of Surgery, IJsselland Ziekenhuis, Capelle aan den IJssel); J. W. de Groot (Department of Oncology, Isala Hospital, Zwolle); T. M. Karsten (Department of Surgery, OLVG, Amsterdam); M. Ledeboer (Department of Gastroenterology and Hepatology, Deventer Ziekenhuis, Deventer); E. R. Manusama (Department of Surgery, Medical Centre Leeuwarden, Leeuwarden); I. D. Nagtegaal (Department of Pathology, Radboudumc, Nijmegen); K. C. M. J. Peeters, R. A. E. M. Tollenaar, C. J. H. van de Velde (Department of Surgery, LUMC, Leiden); A. Wagner (Department of Clinical Genetics, Erasmus MC, Rotterdam); M. Westerterp (Department of Surgery, MC Haaglanden, Den Haag).

Acknowledgements

The authors thank all surgeons, registrars, physician assistants and administrative nurses who registered patients in the DCRA. This study was not preregistered with an analysis plan in an independent, institutional registry. The data, analytical methods and study materials of this study are accessible from the DCRA but are not available publicly. The data are made accessible to other authors on reasonable request and with permission of the DCRA.

Disclosure: The authors declare no conflict of interest.

References

1 Costa-Silva L, Brown G. Magnetic resonance imaging of rectal cancer. Magn Reson Imaging Clin N Am 2013; 21: 385–408.
2 Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 2011; 29: 3753–3760.
3 Logan RF, Patrick J, Nickerson C, Coleman L, Rutter MD, von Wagner C; English Bowel Cancer Screening Evaluation Committee. Outcomes of the bowel cancer screening programme (BCSP) in England after the 1 million tests. Gut 2012; 61: 1439–1446.
4 Morino M, Risio M, Bach S, Beets-Tan R, Buijs K, Panis Y et al.; European Association for Endoscopic Surgery; European Society of Coloproctology. Early rectal cancer: the European Association for Endoscopic Surgery (EAES) clinical consensus conference. Surg Endosc 2015; 29: 755–773.
5 Borstlap WAA, van Oostendorp SE, Klaver CEL, Hahnloser D, Cunningham C, Rullier E et al.; Research committee of the European Society of Coloproctology. Organ preservation in rectal cancer: a synopsis of current guidelines. Colorectal Dis 2018; 20: 201–210.
6 Borstlap WA, Tanis PJ, Koedam TW, Marijnen CA, Cunningham C, Dekker E et al. A multi-centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer. BMC Cancer 2016; 16: 513.
7 Stijns RCH, de Graaf EJR, Punt CJA, Nagtegaal ID, Nuyttens JJME, van Meerten E et al. Long-term oncological and functional outcomes of chemoradiotherapy followed by organ-sparing transanal endoscopic microsurgery for distal rectal cancer: the CARTS Study. JAMA Surg 2018; 154: 47–54.
8 Rullier E, Rouanet P, Tuch JJ, Valverde A, Lelong B, Rivoire M et al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. Lancet 2017; 390: 469–479.
9 Moreno CC, Sullivan PS, Mittal PK. MRI evaluation of rectal cancer: staging and restaging. Curr Probl Diagn Radiol 2017; 46: 234–241.
10 Patel RK, Sayers AE, Kumar P, Khuslus S, Razack A, Hunter IA. The role of endorectal ultrasound and magnetic resonance imaging in the management of early rectal lesions in a tertiary center. Clin Colorectal Cancer 2014; 13: 245–250.
11 Van Leersum NJ, Snijders HS, Henneman D, Kolfschoten NE, Gooiker GA, ten Berge MG et al. The Dutch surgical colorectal audit. Eur J Surg Oncol 2013; 39: 1063–1070.
12 Netherlands Comprehensive Cancer Organisation ( IKNL ). Landelijke richtlijn Rectumcarcinoom (2.0); 2008. https://www.nvgic.nl/file/2017/06/Richtlijn-rectumcarcinoom.pdf [accessed 26 January 2020].
13 Netherlands Comprehensive Cancer Organisation ( IKNL ). Landelijke richtlijn Colorectaalcarcinoom (3.0); 2014. https://www.nhg.org/sites/default/files/content/nhg_org/uploads/ colorectaalcarcinoom.pdf [accessed 26 January 2020].
14 Al-Sukhni E, Milot L, Fruitman M, Beyene J, Victor JC, Schmocker S et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol 2012; 19: 2212–2223.
15 Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging – a meta-analysis. Radiology 2004; 232: 773–783.
16 Zhang G, Cai YZ, Xu GH. Diagnostic accuracy of MRI for assessment of T category and circumferential resection margin involvement in patients with rectal cancer: a meta-analysis. Dis Colon Rectum 2016; 59: 789–799.
17 Zhou J, Zhan S, Zhu Q, Gong H, Wang Y, Fan D et al. Prediction of nodal involvement in primary rectal carcinoma without invasion to pelvic structures: accuracy of
preoperative CT, MR, and DWIBS assessments relative to histopathologic findings. *PLoS One* 2014; 9: e92779.

18 Balyasnikova S, Read J, Wotherspoon A, Rasheed S, Tekkis P, Tait D et al. Diagnostic accuracy of high-resolution MRI as a method to predict potentially safe endoscopic and surgical planes in patients with early rectal cancer. *BMJ Open Gastroenterol* 2017; 4: e000151.

19 Balyasnikova S, Brown G. The MRI assessment of SPECC (significant polyps and early colorectal cancer) lesions. *Colorectal Dis* 2019; 21(Suppl 1): 19–22.

20 Rafalensen SR, Sorensen T, Jakobsen A, Bisgaard C, Lindebjerg J. Transrectal ultrasonography and magnetic resonance imaging in the staging of rectal cancer. Effect of experience. *Scand J Gastroenterol* 2008; 43: 440–446.

21 Taylor FG, Swift RI, Blomqvist L, Brown G. A systematic approach to the interpretation of preoperative staging MRI for rectal cancer. *AJR Am J Roentgenol* 2008; 191: 1827–1835.

22 Beets-Tan RGH, Lambregts DMJ, Maas M, Bipat S, Barbaro B, Curvo-Semedo L et al. Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. *Eur Radiol* 2018; 28: 1465–1475.

23 Chan BPH, Patel R, Mbuaghbaw L, Thahane L, Yaghoobi M. EUS versus magnetic resonance imaging in staging rectal adenocarcinoma: a diagnostic test accuracy meta-analysis. *Gastrointest Endosc* 2019; 90: 196–203.e1.

24 Mondal D, Betts M, Cunningham C, Mortensen NJ, Lindsey I, Slater A. How useful is endorectal ultrasound in the management of early rectal carcinoma? *Int J Colorectal Dis* 2014; 29: 1101–1104.

25 Borstlap WA, Coeymans TJ, Tanis PJ, Marijnen CA, Cunningham C, Bemelman WA et al. Meta-analysis of oncological outcomes after local excision of pT1–2 rectal cancer requiring adjuvant (chemo)radiotherapy or completion surgery. *Br J Surg* 2016; 103: 1105–1116.

26 Eid Y, Alves A, Lubrano J, Menahem B. Does previous transanal excision for early rectal cancer impair surgical outcomes and pathologic findings of completion total mesorectal excision? Results of a systematic review of the literature. *J Visc Surg* 2018; 155: 445–452.

27 Roodbeen SX, Penna M, Arnold S, Wynn G, Warusavitarne J, Francis N et al.; UK TaTME Registry Collaborative. A nationwide study on the adoption and short-term outcomes of transanal total mesorectal excision in the UK. *Minerva Chir* 2019; 74: 279–288.

---

**Supporting information**

Additional supporting information can be found online in the Supporting Information section at the end of the article.